Navigation Links
Health Briefs TV Features SFJ Pharmaceuticals
Date:9/20/2013

Coral Springs, FL (PRWEB) September 20, 2013

The producers of Health Briefs TV are pleased to announce that SFJ Pharmaceuticals will be featured in an upcoming segment on "Innovative Drug Development and Clinical Research Driving Improved Patient Care" as part of the show's Medical Minutes series.

Their value of pharmaceuticals is especially evident in the field of oncology, where the speed of development and availability of drugs may offer the first ever treatment, or have significant advantages over existing drugs. With the costs of developing a cancer drug reaching up to one billion dollars, however, many pharmaceutical companies are using a step-by-step approach. They first advance their most promising drugs for one cancer type, line of therapy or stage, and then advance for additional cancer types, lines of therapy or stages, thus delaying the time it takes for life-saving and life-enhancing to get into the hands or physicians and patients.

Additionally, drugs are first developed for the largest markets, like breast and lung cancer. Drugs for other cancer types, like thyroid and kidney, are not as aggressively developed. Years may go by while patients in need wait, without access to life-saving or life-enhancing drugs.

Pleasanton, California-headquartered SFJ Pharmaceuticals has developed a revolutionary model to overcome drug development challenges. The company captures the lost value for pharmaceutical companies and patients, by taking drugs which are proven in one type of cancer, and helping to accelerate them through clinical development for many different types and stages of cancer.

The five-minute Health Briefs TV segment will educate viewers on the importance of efficient drug development, and will feature the innovative model developed by SFJ Pharmaceuticals to make drugs available to more patients, sooner. The segment will highlight several of SFJ's partnerships, including Eisai Pharmaceuticals for Phase III development of their drug, Lenvatinib, to treat 131I-Refractory Differentiated Thyroid Cancer; Pfizer's drug, Dacomitinib, for first-line treatment of non-small cell lung cancer; and Pfizer's drug, Axitinib, for the adjuvant treatment of renal cell carcinoma. For more information about SFJ Pharmaceuticals, please visit http://www.sfj-pharma.com.

Read the full story at http://www.prweb.com/releases/health-briefs-tv-and-sfj/pharmaceuticals-seg/prweb11138064.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Bel Marra Health Reports on Recent Research Finding Prolonged Life in Those Who Receive Corrective Eye Surgery
2. Online USA Doctors/Virtual Doctors Creates Comprehensive Female Health Plan That Prevents Premature Death in Postmenopausal Women
3. Diet Doc Hormone Diets & Weight Loss Plans Now Helps Clients Achieve a Healthy Lifestyle and Eliminate Causes of Weight Gain With Exclusive Diet Pills
4. Gorman Health Group Expert to Outline the Components of a Successful Medicare Advantage Risk-Adjustment Program
5. Zion Health Announces Native Remedy; Ancient Clay Soaps for Sensitive Skin; New Addition to Whole Foods Market Body Care in Andover, MA
6. Best Natural Acne Treatment Review Published by Health Company
7. School of Public Health Receives $390,000 Grant to Study Alcohol Use Among Youth Acquiring HIV
8. CHL to Hold Original Thought-Leadership Series about Need for Hispanics in the Healthcare and Biomedical Fields; City of Hope to Host Signature Event on Their Campus
9. CDPHP Health Plans Ranked As Best in New York State
10. Oakwood Medical Avatar Brings Personalized Health Info to Mobile Devices
11. Online USA Doctors Announces a New Online, Medical Record System That Improves Patient Health Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... 25, 2017 , ... Republicans in the United States Senate on Thursday released ... Care Reconciliation Act. It differs significantly from the American Health Care Act, which the ... committee, or the House will have to take up the Senate version as-is, if ...
(Date:6/24/2017)... , ... June 24, 2017 , ... ... offering genetic testing for medications in select Florida and Texas doctors' offices and ... , This new application of genetic testing recognizes the role genes play in ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality Institute ... Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively coordinate ... Alerts and Dashboards provide near real-time data about patients admitted to and/or discharged ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... The Military ... president's nominee for deputy secretary of Veterans Affairs, retired Marine Col. Thomas G. Bowman. ... Affairs. , Bowman brings an intimacy with the issues and challenges veterans ...
(Date:6/23/2017)... ... , ... The Aesthetic Channel has recently highlighted Dr. Ben Talei’s unique approach ... proprietary technique that he calls the AuraLyft Facelift. The AuraLyft does more ... can expect to look refreshed, rejuvenated, and revitalized. , Dr. Talei’s unique approach ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... , June 14, 2017 The Bio ... City of Fremont and the ... the bio-pharma industry in California ... enabling executive networking, and fostering workforce development. The primary ... and growth of start-ups, as well as small and ...
(Date:6/12/2017)... 12, 2017 Kineta, Inc., a biotechnology company focused ... Vice President of R&D and Head of Virology Kristin ... Preparedness for the Northwest and Beyond meeting sponsored by ... 14, 2017 from 8:30-10:30 AM PDT at the Agora Conference ... Dr. Bedard will be joined by other leaders in ...
(Date:6/9/2017)... PALO ALTO, Calif. , June 9, 2017 /PRNewswire/ ... medical device company focused on the design, manufacture, sale ... updated the market on the progress of its commercial ... AeroForm is now available in more than one hundred ... country. AeroForm offers a needle-free alternative ...
Breaking Medicine Technology: